Werewolf Therapeutics publishes preclinical data on mWTX-330

Werewolf Therapeutics announced the publication in Cancer Immunology Research Online First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 INDUKINE molecule. The article, entitled "mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity," includes preclinical data that demonstrates that mWTX-330 delivers IL-12 selectively to the tumor microenvironment, where it stimulates a potent anti-tumor immune response. Other key findings and data outlined in the article include: mWTX-330 treatment generates a robust, cleavage-dependent anti-tumor immune response in multiple syngeneic tumor models and is well tolerated. mWTX-330 delivery expands the therapeutic window of the IL-12 cytokine. mWTX-330 treatment activates various tumor-infiltrating lymphocyte populations in the MC38 mouse model and results in the transcriptional reprogramming of the tumor microenvironment and the subsequent activation of various tumor-infiltrating effector-cell populations. mWTX-330 treatment expands unique T-cell receptor clones and increases TCR clonality in the tumor microenvironment. mWTX-330 treatment substantially increases mitochondrial activity in tumor infiltrating CD8+ T cells and NK Cells while reducing signs of exhaustion on CD8+ T cells. The fully human WTX-330 INDUKINE molecule is preferentially activated by primary human tumors. Werewolf is currently recruiting patients for a first-in-human, multi-center, open-label Phase 1 clinical trial that will evaluate WTX-330 in patients with advanced or metastatic solid tumors or lymphoma resistant to checkpoint inhibitors or for which checkpoint inhibitors are not approved.